Netris Pharma, a Lyon, France-based clinical-stage biopharmaceutical company, raised €7.5M in funding.
The round, which brought the total amount to €24.4M, saw participation of new investors including EIC Fund.
The company intends to use the funds to reach all endpoints of its clinical development plan and for corporate development purposes.
Led by CEO Patrick Mehlen, Chief Executive Officer, and Fabien Sebille, Chief Business Officer, Netris Pharma is a clinical-stage company that designs and develops anti-cancer therapeutic molecules, particularly monoclonal antibodies, targeting resistance to oncology treatments. Its lead product, NP137, is an advanced product candidate targeting netrin-1. Netris Pharma is evaluating it in five clinical trials in combination with chemotherapies or immunotherapies as a new path to alleviate resistance to these therapies.
FinSMEs
19/12/2023